- Home
- SGBX vs BLRX Comparison
SGBX vs BLRX Comparison
Compare SGBX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGBX | BLRX |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 17.1M |
| IPO Year | 2017 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SGBX | BLRX |
|---|---|---|
| Price | $4.00 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 18.7M | 26.8K |
| Earning Date | 11-14-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,382,896.00 | ★ $12,735,000.00 |
| Revenue This Year | $1,628.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $2.30 |
| 52 Week High | $122.88 | $14.70 |
Technical Indicators
Market Signals| Indicator | SGBX | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 46.51 |
| Support Level | $2.91 | $3.12 |
| Resistance Level | $4.04 | $3.86 |
| Average True Range (ATR) | 1.40 | 0.26 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 26.04 | 30.04 |
Price Performance
Historical ComparisonAbout SGBX Safe & Green Holdings Corp.
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.